Guard Therapeutics today announces that Sara Thuresson has been recruited to a newly created position as Head of Clinical Operations. She held a similar position at Oncopeptides before joining Guard Therapeutics and will take up her new post on 24 May 2021.
Sara Thuresson has a M.Sc. in Biomedicine from the Karolinska Institute and a degree in drug development from Uppsala University. She has more than 15 years’ experience from a series of key positions in clinical drug development at companies including IQVIA, Glionova and Wilson Therapeutics. Prior to her new appointment she was Clinical Operations Director at Oncopeptides. Sara Thuresson will be part of Guard Therapeutics’ management team and will report to the company’s CEO.
“I am happy to welcome Sara Thuresson to Guard Therapeutics. Her broad expertise and experience in clinical drug development and implementation of global clinical studies will be of great value in the continued development of our investigational drug ROSgard,” Guard Therapeutics’ CEO, Tobias Agervald, says.
Guard Therapeutics’ investigational drug ROSgard has been shown in preclinical studies to protect against cell and organ damage, including acute kidney injury, by counteracting oxidative stress and supporting regenerative processes. Several phase 1 studies have been completed with positive outcomes and the company has recently received regulatory approval to start an initial study in the primary target group for treatment – patients undergoing heart surgery who have additional risk factors for acute kidney injury.